Sana Biotechnology, Inc. (NASDAQ:SANA) Director Sells $612,000.00 in Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Sana Biotechnology Stock Up 0.2 %

SANA opened at $4.28 on Friday. The company’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $6.85. Sana Biotechnology, Inc. has a twelve month low of $2.74 and a twelve month high of $12.00. The stock has a market cap of $952.17 million, a price-to-earnings ratio of -2.80 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). As a group, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

A number of institutional investors have recently added to or reduced their stakes in SANA. Algert Global LLC purchased a new position in Sana Biotechnology during the 2nd quarter valued at about $73,000. The Manufacturers Life Insurance Company grew its position in shares of Sana Biotechnology by 8.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 312,031 shares of the company’s stock valued at $1,704,000 after purchasing an additional 23,157 shares in the last quarter. Dark Forest Capital Management LP increased its holdings in shares of Sana Biotechnology by 112.0% in the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after purchasing an additional 14,430 shares during the period. Squarepoint Ops LLC boosted its stake in Sana Biotechnology by 318.8% during the second quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock valued at $691,000 after buying an additional 96,348 shares during the period. Finally, Integral Health Asset Management LLC grew its position in Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after buying an additional 220,000 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Analyst Ratings Changes

SANA has been the subject of a number of analyst reports. HC Wainwright lowered their price target on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Citigroup increased their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Rodman & Renshaw assumed coverage on Sana Biotechnology in a research report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price objective on the stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.